The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma. The study will also investigate whether HPV integration is associated with TRAF3 and CYLD mutations, and whether recurrence prediction improves when looking at HPV integration along with TRAF3 and CYLD mutations.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Recurrence of OPSCC
Timeframe: From date of therapy completion until biopsy-proven recurrence, assessed up to 5 years
Progression-free survival
Timeframe: From beginning or end of treatment until date of CT-detected recurrence or date of death, assessed up to 5 years
Positive Predictive Value
Timeframe: Baseline to up to 5 years
Negative Predictive Value
Timeframe: Baseline to up to 5 years
Quality of Life questionnaire
Timeframe: Baseline until recurrence or up to 5 years